Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
PDL BioPharma, Inc. |
---|---|
Information provided by: | PDL BioPharma, Inc. |
ClinicalTrials.gov Identifier: | NCT00355901 |
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
Condition | Intervention | Phase |
---|---|---|
Ulcerative Colitis |
Drug: Visilizumab (Nuvion®; HuM291) |
Phase II |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 291-420 |
Study First Received: | July 21, 2006 |
Last Updated: | August 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00355901 |
Health Authority: | United States: Food and Drug Administration |
Ulcerative Colitis Colitis Steroid-Refractory Visilizumab Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC) |
Digestive System Diseases Gastrointestinal Diseases Ulcer Colonic Diseases Inflammatory Bowel Diseases |
Colitis, Ulcerative Intestinal Diseases Gastroenteritis Colitis |
Pathologic Processes |